✦ LIBER ✦

642 INDIVIDUALIZED TREATMENT DURATION WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN FOR 24, 30 OR 36 WEEKS IN HCV GENOTYPE1-INFECTED PATIENTS WITH UNDETECTABLE HCV-RNA EARLY DURING THERAPY (INDIV-2 STUDY)

✍ Scribed by C. Sarrazin; S. Schwendy; B. Möller; N. Dikopoulos; P. Buggisch; J. Encke; G. Teuber; T. Goeser; R. Thimme; H. Klinker; W.O. Boecher; E. Schulte-Frohlinde; R. Prinzing; T. Berg; S. Zeuzem

Book ID: 117377650
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60644-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

54 COMPLETELY INDIVIDUALIZED TREATMENT D

54 COMPLETELY INDIVIDUALIZED TREATMENT DURATIONS (24, 30, 36, 42, 48, 60 OR 72 WEEKS) WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS (INDIV-2 STUDY)

✍ C. Sarrazin; S. Schwendy; B. Möller; N. Dikopoulos; P. Buggisch; J. Encke; G. Te 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Predicting treatment outcome following 2

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6

✍ Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

We sought to validate FIB-4 using data retrospectively collected from treatment-naive HIV/HCV patients. The original model was adapted in order to use AST and ALT levels expressed as times the upper limit of normality (ϫULN), as follows: (age [yr] ϫ AST [ϫULN]) ϫ 10/((PLT [10 9 /l]) ϫ (ALT [ϫULN]) 1